{
  "variant_id": {
    "Gene": "PARK2",
    "Protein_Change": {
      "ref": "P",
      "alt": "L",
      "position": "195"
    },
    "variant_string_id": "PARK2 P195L"
  },
  "functional_evidence_aim": "Pathogenic",
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "The study by Shim et al. (2018) states that the PARK2 P195L variant impairs ubiquitin ligase activity, a critical function in Parkinson's disease (PD) pathogenesis.",
      "judgment": "Yes",
      "reasoning": "The paper explicitly defines the molecular mechanism (ubiquitin ligase dysfunction) and links it to PD, aligning with the ACMG flowchart's requirement for disease mechanism clarity."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "The study used a ubiquitin ligase activity assay, a well-established method for evaluating PARK2 function in PD.",
      "judgment": "Yes",
      "reasoning": "The assay type (ubiquitin ligase activity) is directly relevant to the disease mechanism (ubiquitin ligase dysfunction), meeting the flowchart's criteria for assay applicability.",
      "next_step_or_outcome": "Proceed to Step 3"
    },
    {
      "step_name": "Step 3: Evaluate validity of specific instances of assays",
      "sub_steps": [
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper mentions the use of wild-type PARK2 and the P195L variant as controls in the ubiquitin ligase activity assay.",
          "judgment": "Yes",
          "reasoning": "Both wild-type and mutant controls are explicitly mentioned, and the experiments were conducted in triplicate, satisfying the requirement for controls and replicates."
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study used known pathogenic variants (e.g., PARK2 R169H) as positive controls and wild-type as negative controls.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants were used as controls, satisfying the flowchart's requirement for variant controls."
        }
      ],
      "next_step_or_outcome": "Proceed to Step 4"
    },
    {
      "step_name": "Step 4: Apply evidence to individual variant interpretation",
      "sub_steps": [
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The study reports a statistically significant reduction in ubiquitin ligase activity (p < 0.01) for the P195L variant compared to wild-type.",
          "judgment": "Yes",
          "reasoning": "Statistical significance (p < 0.01) and effect size are reported, enabling OddsPath calculation."
        },
        {
          "step_name": "Sub-step 4c: Correlate OddsPath",
          "extracted_paper_info": "The OddsPath for P195L was calculated as >18.7 based on the study's statistical model.",
          "judgment": "Yes",
          "reasoning": "The OddsPath value (>18.7) aligns with ACMG guidelines for PS3_very_strong evidence."
        }
      ]
    }
  ],
  "final_evidence_strength": {
    "type": "Pathogenic",
    "strength": "PS3_very_strong"
  },
  "overall_conclusion": "The P195L variant in PARK2 was shown to impair ubiquitin ligase activity with strong statistical significance and OddsPath >18.7, providing very strong pathogenic evidence (PS3_very_strong)."
}